Trial Outcomes & Findings for Risk of Oxygen During Cardiac Surgery Trial (NCT NCT02361944)

NCT ID: NCT02361944

Last Updated: 2024-02-01

Results Overview

quantified by measuring F2-isoprostanes isofurans following separation from cardiopulmonary bypass or completion of off-pump coronary artery bypass grafting

Recruitment status

COMPLETED

Study phase

PHASE2/PHASE3

Target enrollment

213 participants

Primary outcome timeframe

separation from cardiopulmonary bypass or completion of off-pump coronary artery bypass grafting (approximately 3-5 hours into surgery and intervention)

Results posted on

2024-02-01

Participant Flow

213 patients signed consent. 12 participants were withdrawn prior to randomization. 201 were randomized.

Participant milestones

Participant milestones
Measure
Normoxia
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery. Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
Hyperoxia
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery. Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
Overall Study
STARTED
100
101
Overall Study
COMPLETED
100
100
Overall Study
NOT COMPLETED
0
1

Reasons for withdrawal

Reasons for withdrawal
Measure
Normoxia
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery. Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
Hyperoxia
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery. Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
Overall Study
surgery cancellation
0
1

Baseline Characteristics

Risk of Oxygen During Cardiac Surgery Trial

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Normoxia
n=100 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery. Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
Hyperoxia
n=100 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery. Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
Total
n=200 Participants
Total of all reporting groups
Age, Continuous
66 years
n=99 Participants
64 years
n=107 Participants
66 years
n=206 Participants
Sex: Female, Male
Female
26 Participants
n=99 Participants
34 Participants
n=107 Participants
60 Participants
n=206 Participants
Sex: Female, Male
Male
74 Participants
n=99 Participants
66 Participants
n=107 Participants
140 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
3 Participants
n=99 Participants
1 Participants
n=107 Participants
4 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
97 Participants
n=99 Participants
99 Participants
n=107 Participants
196 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
American Indian or Alaska Native
1 Participants
n=99 Participants
0 Participants
n=107 Participants
1 Participants
n=206 Participants
Race (NIH/OMB)
Asian
0 Participants
n=99 Participants
1 Participants
n=107 Participants
1 Participants
n=206 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Black or African American
7 Participants
n=99 Participants
5 Participants
n=107 Participants
12 Participants
n=206 Participants
Race (NIH/OMB)
White
91 Participants
n=99 Participants
92 Participants
n=107 Participants
183 Participants
n=206 Participants
Race (NIH/OMB)
More than one race
1 Participants
n=99 Participants
2 Participants
n=107 Participants
3 Participants
n=206 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Region of Enrollment
United States
100 participants
n=99 Participants
100 participants
n=107 Participants
200 participants
n=206 Participants
Serum Creatinine
1.04 mg/dl
n=99 Participants
1.08 mg/dl
n=107 Participants
1.06 mg/dl
n=206 Participants

PRIMARY outcome

Timeframe: separation from cardiopulmonary bypass or completion of off-pump coronary artery bypass grafting (approximately 3-5 hours into surgery and intervention)

quantified by measuring F2-isoprostanes isofurans following separation from cardiopulmonary bypass or completion of off-pump coronary artery bypass grafting

Outcome measures

Outcome measures
Measure
Normoxia
n=100 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery. Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
Hyperoxia
n=100 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery. Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
Intraoperative Systemic Oxidative Damage
69 pg/ml
Interval 54.0 to 89.0
83 pg/ml
Interval 62.0 to 108.0

PRIMARY outcome

Timeframe: baseline to postoperative day 2

quantified by change in serum creatinine concentration

Outcome measures

Outcome measures
Measure
Normoxia
n=100 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery. Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
Hyperoxia
n=100 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery. Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
Acute Kidney Injury
-0.01 mg/dl
Interval -0.16 to 0.19
0.01 mg/dl
Interval -0.12 to 0.19

SECONDARY outcome

Timeframe: ICU admission (immediately after arrival in ICU from operating room)

brachial artery flow mediated dilation assessed when patient arrives in ICU after surgery. brachial artery flow mediated dilation is represented as the percent change in brachial artery diameter following 5 minutes of artery occlusion. The entire assessment takes place at ICU admission.

Outcome measures

Outcome measures
Measure
Normoxia
n=100 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery. Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
Hyperoxia
n=100 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery. Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
Vascular Reactivity / Endothelial Function (as Measured by Flow Mediated Dilation)
4.50 percentage change
Interval 1.22 to 8.12
4.71 percentage change
Interval 1.8 to 9.68

SECONDARY outcome

Timeframe: up to 2 days following surgery

Population: Analyzed in subjects with tissue available

mitochondrial function in atrial myocardium estimated by quantifying adenylate kinase at the end of surgery and oxygen intervention

Outcome measures

Outcome measures
Measure
Normoxia
n=14 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery. Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
Hyperoxia
n=14 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery. Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
Mitochondrial Function
1884 Absorbance Units (AU)
Interval 1745.0 to 2236.0
1936 Absorbance Units (AU)
Interval 1591.0 to 2078.0

SECONDARY outcome

Timeframe: from surgery to hospital discharge, average of 6 days following surgery

defined as any atrial fibrillation following surgery until hospital discharge assessed using continuous telemetry, rhythm strips, and electrocardiograms

Outcome measures

Outcome measures
Measure
Normoxia
n=100 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery. Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
Hyperoxia
n=100 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery. Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
Number of People With Arrhythmia
37 Participants
46 Participants

SECONDARY outcome

Timeframe: morning of postoperative day 1

plasma concentration of creatine kinase, myocardial band

Outcome measures

Outcome measures
Measure
Normoxia
n=100 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery. Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
Hyperoxia
n=100 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery. Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
Myocardial Injury or Infarction
27.2 ng/ml
Interval 11.5 to 58.3
24.5 ng/ml
Interval 13.4 to 40.8

SECONDARY outcome

Timeframe: from surgery to hospital discharge, average of 6 days following surgery

Defined as new deficit on neurologic exam and confirmed with radiologic evidence occurring at any point prior to hospital discharge

Outcome measures

Outcome measures
Measure
Normoxia
n=100 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery. Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
Hyperoxia
n=100 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery. Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
Number of People With Stroke
1 Participants
2 Participants

SECONDARY outcome

Timeframe: up to 18 months following surgery

Population: Assessed in participants available for long-term follow-up who were able to complete cognitive assessments

Median change scores at the Short Blessed Scale (SBT) administered one-year following surgery. The SBT is a validated rating scale, administered by the clinician, measuring the cognitive performance. Sum Total (range 0-28) with 0 indicating no cognitive impairment and 28 indicating severe cognitive impairment.

Outcome measures

Outcome measures
Measure
Normoxia
n=57 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery. Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
Hyperoxia
n=62 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery. Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
Postoperative Cognitive Dysfunction
3 score on a scale
Interval 0.0 to 6.0
2 score on a scale
Interval 0.0 to 4.0

SECONDARY outcome

Timeframe: from surgery to hospital discharge, average of 6 days following surgery

reintubation

Outcome measures

Outcome measures
Measure
Normoxia
n=100 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery. Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
Hyperoxia
n=100 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery. Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
Respiratory Failure
5 Participants
1 Participants

SECONDARY outcome

Timeframe: 12 months following surgery

Population: eGFR assessed in participants available for long-term follow-up

eGFR one year following surgery

Outcome measures

Outcome measures
Measure
Normoxia
n=57 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery. Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
Hyperoxia
n=69 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery. Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
Chronic Kidney Disease
63.0 ml/min/1.73 meters squared
Interval 50.8 to 84.8
60.4 ml/min/1.73 meters squared
Interval 44.3 to 84.4

SECONDARY outcome

Timeframe: up to 2 days following surgery

Estimated by quantifying plasma concentration of plasminogen activator inhibitor-1 (PAI-1)

Outcome measures

Outcome measures
Measure
Normoxia
n=100 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery. Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
Hyperoxia
n=100 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery. Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
Inflammation
31.08 ng/ml
Interval 25.23 to 40.08
36.62 ng/ml
Interval 27.54 to 44.93

SECONDARY outcome

Timeframe: separation from cardiopulmonary bypass or completion of off-pump coronary artery bypass grafting (approximately 3-5 hours into surgery and intervention)

plasma free hemoglobin

Outcome measures

Outcome measures
Measure
Normoxia
n=100 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery. Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
Hyperoxia
n=100 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery. Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
Hemolysis
388,030 ng/ml
433,274 ng/ml

SECONDARY outcome

Timeframe: end of surgery, defined as immediately after separation from cardiopulmonary bypass or completion of off-pump coronary artery bypass grafting (approximately 3-5 hours into surgery and intervention)

TMH electron spin probe

Outcome measures

Outcome measures
Measure
Normoxia
n=100 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery. Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
Hyperoxia
n=100 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery. Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
Reactive Oxygen Species Production
165,000 Absorbance Units (AU)
180,100 Absorbance Units (AU)

SECONDARY outcome

Timeframe: from surgery to hospital discharge, average of 6 days following surgery

The number of participants with acute brain dysfunction as assessed by the Confusion Assessment Method for the ICU (CAM-ICU) twice daily while patients are in the ICU or for first 3 postoperative days.

Outcome measures

Outcome measures
Measure
Normoxia
n=100 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery. Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
Hyperoxia
n=100 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery. Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
Acute Brain Dysfunction (Delirium)
16 Participants
22 Participants

SECONDARY outcome

Timeframe: ICU admission (immediately after arrival in ICU from operating room)

arterial lactate measured from arterial blood collected at ICU admission (immediately after arrival in ICU from operating room)

Outcome measures

Outcome measures
Measure
Normoxia
n=100 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery. Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
Hyperoxia
n=100 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery. Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
Oxygenation and Perfusion (Lactate)
1.5 mmol/liter
Interval 1.2 to 2.3
1.8 mmol/liter
Interval 1.3 to 2.9

SECONDARY outcome

Timeframe: up to 7 days following surgery

KDIGO acute kidney injury is defined as an increase in SCr ≥ 0.3 mg/dL (≥ 26.5 lmol/L) within 48 hours of surgery or 1.5 to 1.9 times baseline within 7 days of surgery

Outcome measures

Outcome measures
Measure
Normoxia
n=100 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery. Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
Hyperoxia
n=100 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery. Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
Acute Kidney Injury, According to KDIGO Criteria
21 Participants
21 Participants

SECONDARY outcome

Timeframe: baseline to 2 days following surgery

Urinary concentration of \[TIMP2\]\*\[IGFBP7\] 6 hours after ICU admission

Outcome measures

Outcome measures
Measure
Normoxia
n=100 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery. Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
Hyperoxia
n=100 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery. Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
Acute Kidney Injury Estimated by Urine Concentration of TIMP-2 IGFBP7
0.224 (ng/ml) squared
Interval 0.112 to 0.486
0.187 (ng/ml) squared
Interval 0.075 to 0.423

SECONDARY outcome

Timeframe: baseline to 2 days following surgery

Urinary concentration of neutrophil gelatinase-associated lipocalin (NGAL) 6 hours after ICU admission.

Outcome measures

Outcome measures
Measure
Normoxia
n=100 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery. Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
Hyperoxia
n=100 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery. Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
Acute Kidney Injury Estimated by Urine Concentration of NGAL
6.9 ng/ml
Interval 3.0 to 17.5
4.8 ng/ml
Interval 2.9 to 14.1

SECONDARY outcome

Timeframe: end of surgery, defined as immediately after separation from cardiopulmonary bypass or completion of off-pump coronary artery bypass grafting (approximately 3-5 hours into surgery and intervention)

CAT1H electron spin probe

Outcome measures

Outcome measures
Measure
Normoxia
n=100 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery. Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
Hyperoxia
n=100 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery. Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
Reactive Oxygen Species Production
17,300 Absorbance Units (AU)
Interval 8138.0 to
17,040 Absorbance Units (AU)
Interval 9788.0 to

SECONDARY outcome

Timeframe: during surgery

hemoglobin O2 saturation summarized using SpO2 data continuously measured and recorded every minute during surgery. We calculated the median SpO2 throughout surgery using all the minute to minute values. For example, if a participant had a 5 hour (300 minutes) long surgery, the participant would have 300 SpO2 measurements. We calculated and report the median of those measurements.

Outcome measures

Outcome measures
Measure
Normoxia
n=100 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery. Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
Hyperoxia
n=100 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery. Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
Oxygenation and Perfusion (SpO2)
97 percent saturation
Interval 97.0 to 98.0
100 percent saturation
Interval 100.0 to 100.0

SECONDARY outcome

Timeframe: end of surgery, defined as separation from cardiopulmonary bypass or completion of off-pump coronary artery bypass grafting (approximately 3-5 hours into surgery and intervention)

partial pressure of oxygen in arterial blood measured from blood sampled at end of surgery, defined as following separation from cardiopulmonary bypass or completion of off-pump coronary artery bypass grafting (approximately 3-5 hours into surgery and intervention)

Outcome measures

Outcome measures
Measure
Normoxia
n=100 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery. Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
Hyperoxia
n=100 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery. Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
Oxygenation and Perfusion (PaO2)
99 mmHg
Interval 96.0 to 105.0
377 mmHg
Interval 332.0 to 426.0

SECONDARY outcome

Timeframe: continuously assessed throughout surgery and recorded each minute

brain hemoglobin oxygenation using near-infrared spectroscopy (NIRS). The median percent changes from baseline (baseline measured at beginning of surgery when probes placed on forehead, prior to intervention) throughout surgery was calculated using cerebral oximetry measurements collected every minute throughout surgery. We calculated the difference between baseline and each measurement throughout surgery. For example, if a participant had a 5 hour (300 minutes) long surgery, the participant would have 300 cerebral oximetry measurements. We calculated and report the median of those measurements.

Outcome measures

Outcome measures
Measure
Normoxia
n=100 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery. Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
Hyperoxia
n=100 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery. Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
Oxygenation and Perfusion (Cerebral Oximetry)
-7.2 percentage change from baseline
Interval -14.4 to -0.2
6.0 percentage change from baseline
Interval 0.0 to 14.4

SECONDARY outcome

Timeframe: end of surgery, defined as following separation from cardiopulmonary bypass or completion of off-pump coronary artery bypass grafting (approximately 3-5 hours into surgery and intervention)

mixed venous O2 saturation, measured from blood sampled from pulmonary artery sampled at end of surgery, defined as following separation from cardiopulmonary bypass or completion of off-pump coronary artery bypass grafting (approximately 3-5 hours into surgery and intervention)

Outcome measures

Outcome measures
Measure
Normoxia
n=100 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery. Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
Hyperoxia
n=100 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery. Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
Oxygenation and Perfusion (SvO2)
68 percent saturation
Interval 65.0 to 73.0
78 percent saturation
Interval 71.0 to 83.0

SECONDARY outcome

Timeframe: end of surgery, defined as immediately after separation from cardiopulmonary bypass or completion of off-pump coronary artery bypass grafting (approximately 3-5 hours into surgery and intervention)

cardiac output (normalized to body surface area, i.e., cardiac index)

Outcome measures

Outcome measures
Measure
Normoxia
n=100 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery. Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
Hyperoxia
n=100 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery. Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
Oxygenation and Perfusion (Cardiac Index)
2.56 liters/min/meter squared
Interval 2.14 to 2.88
2.48 liters/min/meter squared
Interval 1.96 to 3.14

SECONDARY outcome

Timeframe: ICU admission (immediately after arrival in ICU from operating room)

reactive hyperemia index measured at ICU admission (immediately after arrival in ICU from operating room). The reactive hyperemia index is a number generated by an endopat machine performing peripheral artery tonometry. The index ranges from approximately 1-3, where higher values indicate better vascular reactivity and endothelial function.

Outcome measures

Outcome measures
Measure
Normoxia
n=100 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery. Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
Hyperoxia
n=100 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery. Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
Vascular Reactivity / Endothelial Function (Peripheral Artery Tonometry)
1.41 index
Interval 1.14 to 1.78
1.23 index
Interval 0.91 to 1.65

SECONDARY outcome

Timeframe: tissue collected during surgery when heart is exposed approximately 2 hours into intervention

Effective concentration for 50% dilation acetylcholine dose response, tension wire myography from arterioles dissected from epicardial fat

Outcome measures

Outcome measures
Measure
Normoxia
n=100 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery. Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
Hyperoxia
n=100 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery. Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
Vascular Reactivity / Endothelial Function (Tension Wire Myography, Endothelial Dependent Vasodilation, EC50)
-6.13 log Molar
Interval -6.57 to -5.7
-5.92 log Molar
Interval -6.36 to -5.48

SECONDARY outcome

Timeframe: tissue collected during surgery when heart is exposed approximately 2 hours into intervention

Maximum percentage of arteriole dilation after increasing doses of acetylcholine measured using tension wire myography of arterioles dissected from epicardial fat. The fat sample was collected during surgery when heart is exposed approximately 2 hours into intervention.

Outcome measures

Outcome measures
Measure
Normoxia
n=100 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery. Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
Hyperoxia
n=100 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery. Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
Vascular Reactivity / Endothelial Function (Tension Wire Myography, Endothelial Dependent Vasodilation, Emax)
36.2 percent relaxation
Interval 25.5 to 46.9
39.5 percent relaxation
Interval 24.5 to 51.5

SECONDARY outcome

Timeframe: tissue collected during surgery when heart is exposed approximately 2 hours into intervention

Effective concentration for 50% dilation sodium nitroprusside dose response, tension wire myography from arterioles dissected from epicardial fat

Outcome measures

Outcome measures
Measure
Normoxia
n=100 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery. Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
Hyperoxia
n=100 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery. Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
Vascular Reactivity / Endothelial Function (Tension Wire Myography, Endothelial Independent Vasodilation, EC50)
-6.95 log Molar
Interval -7.37 to -6.53
-5.75 log Molar
Interval -6.21 to -5.29

SECONDARY outcome

Timeframe: tissue collected during surgery when heart is exposed approximately 2 hours into intervention

Maximum percentage of arteriole dilation after increasing doses of sodium nitroprusside measured using tension wire myography of arterioles dissected from epicardial fat. The fat sample was collected during surgery when heart is exposed approximately 2 hours into intervention.

Outcome measures

Outcome measures
Measure
Normoxia
n=100 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery. Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
Hyperoxia
n=100 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery. Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
Vascular Reactivity / Endothelial Function (Tension Wire Myography, Endothelial Independent Vasodilation, Emax)
91.5 percent relaxation
Interval 83.8 to 99.2
92.6 percent relaxation
Interval 82.8 to 102.4

SECONDARY outcome

Timeframe: tissue collected during surgery when heart is exposed approximately 2 hours into intervention

Effective concentration for 50% dilation cinaciguat dose response, tension wire myography from arterioles dissected from epicardial fat

Outcome measures

Outcome measures
Measure
Normoxia
n=100 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery. Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
Hyperoxia
n=100 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery. Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
Vascular Reactivity / Endothelial Function (Tension Wire Myography, sGC Activation Vasodilation, EC50)
-6.89 log Molar
Interval -7.48 to -6.3
-6.66 log Molar
Interval -7.2 to -6.12

SECONDARY outcome

Timeframe: tissue collected during surgery when heart is exposed approximately 2 hours into intervention

Maximum percentage of arteriole dilation after increasing doses of cinaciguat measured using tension wire myography of arterioles dissected from epicardial fat. The fat sample was collected during surgery when heart is exposed approximately 2 hours into intervention.

Outcome measures

Outcome measures
Measure
Normoxia
n=100 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery. Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
Hyperoxia
n=100 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery. Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
Vascular Reactivity / Endothelial Function (Tension Wire Myography, sGC Activation Vasodilation, Emax)
97.1 percent relaxation
Interval 92.9 to 101.4
96.0 percent relaxation
Interval 91.9 to 100.2

SECONDARY outcome

Timeframe: end of surgery, defined as immediately after separation from cardiopulmonary bypass or completion of off-pump coronary artery bypass grafting (approximately 3-5 hours into surgery and intervention)

Plasminogen activator inhibitor 1

Outcome measures

Outcome measures
Measure
Normoxia
n=100 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery. Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
Hyperoxia
n=100 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery. Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
Vascular Reactivity / Endothelial Function (PAI-1)
31.2 ng/ml
Interval 25.2 to 40.1
36.6 ng/ml
Interval 27.5 to 44.9

SECONDARY outcome

Timeframe: end of surgery, defined as immediately after separation from cardiopulmonary bypass or completion of off-pump coronary artery bypass grafting (approximately 3-5 hours into surgery and intervention)

E-selectin

Outcome measures

Outcome measures
Measure
Normoxia
n=100 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery. Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
Hyperoxia
n=100 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery. Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
Vascular Reactivity / Endothelial Function (E-selectin)
16.4 ng/ml
Interval 11.0 to 19.7
16.2 ng/ml
Interval 11.3 to 25.0

Adverse Events

Normoxia

Serious events: 8 serious events
Other events: 80 other events
Deaths: 2 deaths

Hyperoxia

Serious events: 11 serious events
Other events: 80 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
Normoxia
n=100 participants at risk
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery. Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
Hyperoxia
n=100 participants at risk
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery. Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
Cardiac disorders
Category: Arrythmia, Pacemaker or Cardiac Arrest
3.0%
3/100 • Number of events 3 • baseline to one year following surgery
5.0%
5/100 • Number of events 5 • baseline to one year following surgery
Respiratory, thoracic and mediastinal disorders
Hypoxia
0.00%
0/100 • baseline to one year following surgery
1.0%
1/100 • Number of events 1 • baseline to one year following surgery
Cardiac disorders
right ventricular failure
0.00%
0/100 • baseline to one year following surgery
1.0%
1/100 • Number of events 1 • baseline to one year following surgery
Blood and lymphatic system disorders
heparin-induced thrombocytopenia
0.00%
0/100 • baseline to one year following surgery
1.0%
1/100 • Number of events 1 • baseline to one year following surgery
Immune system disorders
anaphylaxis
0.00%
0/100 • baseline to one year following surgery
1.0%
1/100 • Number of events 1 • baseline to one year following surgery
Respiratory, thoracic and mediastinal disorders
Pleural effusion
0.00%
0/100 • baseline to one year following surgery
1.0%
1/100 • Number of events 1 • baseline to one year following surgery
Nervous system disorders
Seizure
2.0%
2/100 • Number of events 2 • baseline to one year following surgery
1.0%
1/100 • Number of events 1 • baseline to one year following surgery
Surgical and medical procedures
Surgical complications requiring valve replacement revision
2.0%
2/100 • Number of events 2 • baseline to one year following surgery
0.00%
0/100 • baseline to one year following surgery
Psychiatric disorders
Severe postoperative hallucinations
1.0%
1/100 • Number of events 1 • baseline to one year following surgery
0.00%
0/100 • baseline to one year following surgery

Other adverse events

Other adverse events
Measure
Normoxia
n=100 participants at risk
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery. Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
Hyperoxia
n=100 participants at risk
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery. Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
Immune system disorders
Fever
9.0%
9/100 • Number of events 9 • baseline to one year following surgery
6.0%
6/100 • Number of events 6 • baseline to one year following surgery
Cardiac disorders
Tachycardia
5.0%
5/100 • Number of events 5 • baseline to one year following surgery
8.0%
8/100 • Number of events 8 • baseline to one year following surgery
Vascular disorders
Hypotension
29.0%
29/100 • Number of events 29 • baseline to one year following surgery
25.0%
25/100 • Number of events 25 • baseline to one year following surgery
Vascular disorders
Vasoplegia
34.0%
34/100 • Number of events 34 • baseline to one year following surgery
28.0%
28/100 • Number of events 28 • baseline to one year following surgery
Cardiac disorders
Decreased cardiac output
2.0%
2/100 • Number of events 2 • baseline to one year following surgery
5.0%
5/100 • Number of events 5 • baseline to one year following surgery
Blood and lymphatic system disorders
Anemia
49.0%
49/100 • Number of events 49 • baseline to one year following surgery
48.0%
48/100 • Number of events 48 • baseline to one year following surgery
Blood and lymphatic system disorders
Leukocytosis
37.0%
37/100 • Number of events 37 • baseline to one year following surgery
47.0%
47/100 • Number of events 47 • baseline to one year following surgery
Blood and lymphatic system disorders
Thrombocytopenia
1.0%
1/100 • Number of events 1 • baseline to one year following surgery
1.0%
1/100 • Number of events 1 • baseline to one year following surgery

Additional Information

Frederic T. BIllings IV

Vanderbilt University

Phone: 6159368487

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place